Premsai Kumar1,2, Rahul Mhaskar2, Richard Kim3, Daniel Anaya3, Jessica Frakes4, Sarah Hoffe4, Junsung Choi1, Bela Kis1. 1. Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA. 2. University of South Florida Morsani College of Medicine, Tampa, FL, USA. 3. Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA. 4. Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Abstract
Background: There is no curative treatment option for patients with unresectable intrahepatic, cholangiocarcinoma (IHC). The aim of this study was to evaluate the efficacy of; radiation segmentectomy/lobectomy using Y90-labeled glass microspheres in patients with; unresectable IHC. Methods: This IRB-approved, single-center study included, 16 patients (age: 67 ± 7.7 years) with IHC who received radiation segmentectomy or lobectomy, treatment using Y90-labeled glass microspheres between May 2009 and October 2019. Radiation, segmentectomy/lobectomy was defined as at least 190 Gy dose delivered into treated liver; volume. Results: The median OS from IHC diagnosis was 22.7 months (95% CI: 13.9-66.1) and from, radioembolization it was 7 months (95% CI: 4.33-54.17). Patients who did not receive, chemotherapy before the radioembolization had significantly longer median OS (26.8 vs. 5.9, months, P = 0.03). Four patients had >20 months survival after radioembolization, including 2, patients with survival of 42 and 54 months. There was no 30-day mortality and no severe, complications. Conclusion: Radiation segmentectomy/lobectomy is safe with minimal side effects. The median, OS of the study group is modest; however, 4 patients (25%) showed excellent survival. These results suggest a need for a larger study to define the IHC patient group who could, most benefit from this procedure.
Background: There is no curative treatment option for patients with unresectable intrahepatic, cholangiocarcinoma (IHC). The aim of this study was to evaluate the efficacy of; radiation segmentectomy/lobectomy using Y90-labeled glass microspheres in patients with; unresectable IHC. Methods: This IRB-approved, single-center study included, 16 patients (age: 67 ± 7.7 years) with IHC who received radiation segmentectomy or lobectomy, treatment using Y90-labeled glass microspheres between May 2009 and October 2019. Radiation, segmentectomy/lobectomy was defined as at least 190 Gy dose delivered into treated liver; volume. Results: The median OS from IHC diagnosis was 22.7 months (95% CI: 13.9-66.1) and from, radioembolization it was 7 months (95% CI: 4.33-54.17). Patients who did not receive, chemotherapy before the radioembolization had significantly longer median OS (26.8 vs. 5.9, months, P = 0.03). Four patients had >20 months survival after radioembolization, including 2, patients with survival of 42 and 54 months. There was no 30-day mortality and no severe, complications. Conclusion: Radiation segmentectomy/lobectomy is safe with minimal side effects. The median, OS of the study group is modest; however, 4 patients (25%) showed excellent survival. These results suggest a need for a larger study to define the IHC patient group who could, most benefit from this procedure.
Authors: Mizuki Nishino; Jyothi P Jagannathan; Nikhil H Ramaiya; Annick D Van den Abbeele Journal: AJR Am J Roentgenol Date: 2010-08 Impact factor: 3.959
Authors: Riad Salem; Robert J Lewandowski; Vanessa L Gates; Charles W Nutting; Ravi Murthy; Steven C Rose; Michael C Soulen; Jean-Francois H Geschwind; Laura Kulik; Yun Hwan Kim; Carlo Spreafico; Marco Maccauro; Lourens Bester; Daniel B Brown; Robert K W Ryu; Daniel Y Sze; William S Rilling; Kent T Sato; Bruno Sangro; Jose Ignacio Bilbao; Tobias F Jakobs; Samer Ezziddin; Suyash Kulkarni; Aniruddha Kulkarni; David M Liu; David Valenti; Philip Hilgard; Gerald Antoch; Stefan P Muller; Hamad Alsuhaibani; Mary F Mulcahy; Marta Burrel; Maria Isabel Real; Stewart Spies; Abdulredha A Esmail; Jean-Luc Raoul; Etienne Garin; Mathew S Johnson; Al B Benson; Ricky A Sharma; Harpreet Wasan; Bieke Lambert; Khairuddin Memon; Andrew S Kennedy; Ahsun Riaz Journal: J Vasc Interv Radiol Date: 2011-03 Impact factor: 3.464
Authors: Robert J Lewandowski; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald A Mora; Laura Kulik; Daniel Ganger; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Juan Carlos Caicedo; Michael Abecassis; Ahsun Riaz; Riad Salem Journal: Radiology Date: 2018-04-24 Impact factor: 11.105
Authors: Gaya Spolverato; Yuhree Kim; Sorin Alexandrescu; Hugo P Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Thuy B Tran; J Wallis Marsh; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2015-06-10 Impact factor: 5.344
Authors: Tamer M Shaker; Chloe Chung; Manish K Varma; Michael G Doherty; Andrea M Wolf; Mathew H Chung; M Mura Assifi Journal: Am J Surg Date: 2018-02-02 Impact factor: 2.565
Authors: Ron C Gaba; Robert J Lewandowski; Laura M Kulik; Ahsun Riaz; Saad M Ibrahim; Mary F Mulcahy; Robert K Ryu; Kent T Sato; Vanessa Gates; Michael M Abecassis; Reed A Omary; Talia B Baker; Riad Salem Journal: Ann Surg Oncol Date: 2009-04-09 Impact factor: 5.344
Authors: Kerri A Simo; Laura E Halpin; Nicole M McBrier; Jacob A Hessey; Erin Baker; Samuel Ross; Ryan Z Swan; David A Iannitti; John B Martinie Journal: J Surg Oncol Date: 2016-01 Impact factor: 3.454
Authors: Alexandra Gangi; Jehan Shah; Nathan Hatfield; Johnna Smith; Jennifer Sweeney; Junsung Choi; Ghassan El-Haddad; Benjamin Biebel; Nainesh Parikh; Bulent Arslan; Sarah E Hoffe; Jessica M Frakes; Gregory M Springett; Daniel A Anaya; Mokenge Malafa; Dung-Tsa Chen; Yunyun Chen; Richard D Kim; Ravi Shridhar; Bela Kis Journal: J Vasc Interv Radiol Date: 2018-07-02 Impact factor: 3.464